Glenmark gets USFDA nod for skin ointment

By: |
New Delhi | Published: September 19, 2017 4:01:20 PM

Glenmark Pharmaceuticals today said it has received approval from the US health regulator for Desonide ointment used for treatment of various skin problems including allergy and rashes.

Glenmark Pharmaceuticals, Glenmark, Pharmaceuticals, US health regulator, Desonide ointment, skin problems, allergy, rashesGlenmark Pharmaceuticals today said it has received approval from the US health regulator for Desonide ointment used for treatment of various skin problems including allergy and rashes. (Representative Image/Reuters)

Glenmark Pharmaceuticals today said it has received approval from the US health regulator for Desonide ointment used for treatment of various skin problems including allergy and rashes. Glenmark Pharmaceuticals Inc has been granted final approval by the United States Food & Drug Administration (US FDA) for Desonide ointment, 0.05 per cent, the company said in a statement. The company’s product is a generic version of Desonide ointment 0.05 per cent of Perrigo New York Inc. As per IMS Health sales data for the period ending July 2017, Desonide ointment, had annual sales of approximately USD 23.4 million. Glenmark’s current portfolio consists of 124 products authorised for distribution in the US and 62 ANDA’s pending approval with the USFDA, the company said. The stock was trading 1.61 per cent up at Rs 616.70 apiece on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.